-

FUJIFILM Irvine Scientific Introduces Sterile Express Media Service

The first manufacturing service of its kind delivers tested sterile, non-GMP media designed for feasibility testing before scale-up, to support development of cell and gene therapies

SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Irvine Scientific, Inc., today announced the launch of Sterile Express Media Service (SEMS), for small-scale, rapid production of non-GMP media tested for sterility. With SEMS, customers can request up to 100L of media, to be rapidly manufactured in a Grade A/ISO 5 sterile environment, and have it shipped within 15 business days pending sterility confirmation.

Contamination in culture media can affect cell characteristics such as growth, metabolism, and morphology, contributing to unreliable or erroneous results. This can cause delays in the development and scale-up process. SEMS has been introduced to enable manufacturers to test the feasibility of formulations using sterile cell culture media before scale-up to more costly GMP manufacturing. Sterile media provide an extra measure of control and security for valuable cells and streamline the successful development of cell and gene therapies and biopharmaceutical drugs.

Unlike the sterile-filtered and sterile-tested media currently available in the market, SEMS utilizes isolator technology to provide an aseptic manufacturing environment. SEMS media remain in a Grade A/ISO 5 environment throughout the manufacturing process, reducing the risk of contamination for critical applications. The non-GMP liquid media formulations are manufactured using the same qualified raw materials used for GMP manufacturing and are sterility tested according to USP71 and ISO 13408 requirements.

Erik Vaessen, Ph.D., Executive Director, Life Sciences at FUJIFILM Irvine Scientific commented: “Until now, there has never been a rapid, non-GMP manufacturing service that delivers sterile cell culture media. Sterile Express Media Service is a first-of-its-kind offering that enables FUJIFILM Irvine Scientific customers to use sterile media for trials, which may also help reduce costs associated with developing therapies and biopharmaceutical drugs by reducing contamination risk during the testing phase. We are pleased to offer this innovation to our customers.”

SEMS is part of the FUJIFILM Irvine Scientific group of media services that also include Express Media Service (EMS) for small-scale, rapid production of non-GMP media and Media Development and Optimization Services (MDO) for the development of custom media.

Contacts

Lorna Cuddon
Zyme Communications
Phone: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com

FUJIFILM Irvine Scientific


Release Versions

Contacts

Lorna Cuddon
Zyme Communications
Phone: +44 (0)7811996942
Email: lorna.cuddon@zymecommunications.com

More News From FUJIFILM Irvine Scientific

CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing

KAWASAKI, Japan & SANTA ANA, Calif.--(BUSINESS WIRE)--Chitose Laboratory Corp., (CHITOSE), a leading company of the bioeconomy and provider of advanced cell line development services, and FUJIFILM Biosciences Inc., a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production. CHITOSE’s expertise in cell line development usi...

FUJIFILM Biosciences Introduces BalanCD HEK293 Perfusion A Medium to Enable Gene Therapy Production

SANTA ANA, Calif.--(BUSINESS WIRE)--FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A. Designed to expand and augment the company’s portfolio of gene therapy application solutions, BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology to provide reliable, efficient, and scalable production of viral vectors for development of...

Fujifilm Rebrands Life Sciences Companies to Strengthen Position as Strategic Partners for Life, Offering End-to-End Solutions

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, today announced new names and identities as part of a strategic positioning effort. The Group Companies’ new names, collaborative strategic focus, and structural alignment reflects Fujifilm’s commitment to Life Sciences, offering fully integrated...
Back to Newsroom